DDInter281 DDInter1657
Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of systemic therapy. The FDA approved Selinexor in June 2019. The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Canakinumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Canakinumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Canakinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alprazolam
Canakinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tuberculin purified protein derivative
Canakinumab {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Canakinumab {u} may lead to a major life threatening interaction when taken with {v} Satralizumab
Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Canakinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Canakinumab may lead to a major life threatening interaction when taken with Natalizumab
Canakinumab may lead to a major life threatening interaction when taken with Satralizumab